A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of Olezarsen (ISIS 678354) Administered Subcutaneously to Patients with Severe Hypertriglyceridemia

Date Added
July 18th, 2023
PRO Number
Pro00127774
Researcher
Marc-Andre Cornier

List of Studies

Keywords
Cardiovascular, Cholesterol, Drug Studies, Men's Health, Women's Health
Summary

This clinical research study is enrolling adults who have high triglycerides (fats in the blood). The study drug, olezarsen, is an investigational drug designed to reduce triglyceride blood levels. If you meet the requirements to participate in this study, you will be randomly assigned to receive either olezarsen or placebo (an inactive substance that contains no drug). During the treatment period, participants will be asked to complete visits every 4 weeks to include a total of 21 visits over approximately 16 months. If eligible, study medication and study visits will be provided free of charge. Compensation is available.

Institution
MUSC
Recruitment Contact
Kelcey Ladner
843-792-6043
ladnerk@musc.edu



-- OR --